Showing 8331-8340 of 9142 results for "".
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasishttps://practicaldermatology.com/news/global-psoriasis-survey-85-of-us-respondents-faced-social-stigma-because-of-psoriasis/2458514/Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have suffered from social stigma like discrimination and humiliation because of their disease. In additi
- Daily ‘Soak and Smear' OKed for Kids with Eczemahttps://practicaldermatology.com/news/daily-soak-and-smear-oked-for-kids-with-eczema/2458513/Daily bathing is fine for children with eczema as long as it's followed by lots of moisturizer, according to a new article in Annals of Allergy, Asthma and Immunology. Researchers led by Portl
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Regenica® Rejuvenating Dual Serum Improves Skin Texture, Tone Through 90 Dayshttps://practicaldermatology.com/news/regenica-rejuvenating-dual-serum-improves-skin-texture-tone-through-90-days/2458521/New research shows that Regenica® Rejuvenating Dual Serum starts working at as early as 14 days, with continued improvement seen through 90 days. In the study, statistically significant improvements were reported as early as 14 days, wi
- Alopecia Areata May Protect Against Stroke, Heart Attackhttps://practicaldermatology.com/news/alopecia-areata-may-protect-against-stroke-heart-attack/2458522/Unlike other inflammatory dermatologic conditions, alopecia areata does not appear to increase risk for cardiovascular disease, and it may even protect against stroke, new research suggests. Researchers compared 1,377 alopecia areata patients to 4,131 control subjects. They found th
- Sciton Introduces diVa Laser for Vaginal Rejuvenationhttps://practicaldermatology.com/news/sciton-introduced-diva-laser-for-vaginal-rejuvenation/2458524/Sciton introduced diVa, a hybrid fractional laser (HFL) for the treatment of vaginal tissue. Major life events like childbirth and menopause can cause changes in vaginal health. Excessive stretching of the vaginal tissue commonly happens from childbirth. Vaginal tissue may not fully recov
- New Hair Restoration Group Started for Dermatologists, Facial Plastic Surgeons and Plastic Surgeonshttps://practicaldermatology.com/news/new-hair-restoration-group-started-for-dermatologists-facial-plastic-surgeons-and-plastic-surgeons/2458525/Introducing The North American Society for Hair Restoration (NASHR), a new non-profit medical association comprising plastic surgeons, facial plastic surgeons and dermatologists who have the proper training for hair transplantation surgery.
- The La Roche-Posay North American Foundation Awards 2016 Grant Winnershttps://practicaldermatology.com/news/the-la-roche-posay-north-american-foundation-awards-2016-grant-winners/2458530/Committed to working alongside dermatologists, La Roche-Posay's North American Fondation encourages residents, fellows and practitioners with at least two years beyond training to develop innovative programs. The brand and a board of certified dermatologists awards two to three w